The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2020 | ICU admission of patients treated with ARI-0001 cells
Valentín Ortiz-Maldonado, MD, Hospital Clinic, Barcelona, Spain, discusses the safety of ARI-0001 cells (varnimcabtagene autoleucel), an academic CD19 CAR T-cell, in patients with CD19+ leukemia or lymphoma refractory to therapy. The clinical trial (NCT03144583) protocol had to be changed due to toxicities, such as cytokine release syndrome (CRS). Dr Ortiz-Maldonado explains how splitting the doses of ARI-cells reduced patients’ admission in the ICU. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
